{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T17:43:59Z","timestamp":1786470239892,"version":"build-2736575974"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.antiviral.2014.08.003","type":"journal-article","created":{"date-parts":[[2014,8,13]],"date-time":"2014-08-13T04:08:53Z","timestamp":1407902933000},"page":"42-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus"],"prefix":"10.1016","volume":"111","author":[{"given":"Scott","family":"Parker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Crump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollyce","family":"Hartzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Hembrador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Randall","family":"Lanier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Painter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Schriewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence C.","family":"Trost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Mark","family":"Buller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2014.08.003_b0005","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1128\/AAC.00678-09","article-title":"ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation","volume":"53","author":"Berhanu","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.08.003_b0010","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.vaccine.2010.10.039","article-title":"Impact of ST-246(R) on ACAM2000 smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice","volume":"29","author":"Berhanu","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.08.003_b0015","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.virol.2003.11.015","article-title":"Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model","volume":"318","author":"Buller","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.08.003_b0020","series-title":"National Institute of Allergy and Infectious Disease: Frontiers in Research","first-page":"145","article-title":"Development of prophylactics and therapeutics against the smallpox and monkeypox biothreat agents","author":"Buller","year":"2008"},{"key":"10.1016\/j.antiviral.2014.08.003_b0025","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0042-6822(92)90445-U","article-title":"Restricted replication of ectromelia virus in cell culture correlates with mutations in virus-encoded host range gene","volume":"187","author":"Chen","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.08.003_b0030","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.virol.2010.10.021","article-title":"Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy","volume":"409","author":"Chen","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.08.003_b0035","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0166-3542(03)00110-4","article-title":"Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney","volume":"59","author":"Ciesla","year":"2003","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.08.003_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(02)00008-6","article-title":"Cidofovir in the treatment of poxvirus infections","volume":"55","author":"De Clercq","year":"2002","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.08.003_b0045","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1177\/135965350701200802","article-title":"Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures","volume":"12","author":"Duraffour","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2014.08.003_b0050","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2014.08.003_b0055","doi-asserted-by":"crossref","first-page":"10889","DOI":"10.1073\/pnas.0804985105","article-title":"Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus","volume":"105","author":"Earl","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.08.003_b0060","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nm1261","article-title":"Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus","volume":"11","author":"Edghill-Smith","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2014.08.003_b0065","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-1-61779-876-4_11","article-title":"Mousepox, a small animal model of smallpox","volume":"890","author":"Esteban","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.antiviral.2014.08.003_b0070","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.virol.2005.09.056","article-title":"Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host","volume":"345","author":"Fang","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.08.003_b0075","series-title":"Smallpox and its eradication","author":"Fenner","year":"1988"},{"key":"10.1016\/j.antiviral.2014.08.003_b0080","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1128\/JVI.78.19.10230-10237.2004","article-title":"Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions","volume":"78","author":"Fogg","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.08.003_b0085","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa020534","article-title":"Clinical responses to undiluted and diluted smallpox vaccine","volume":"346","author":"Frey","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.08.003_b0090","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.1016\/j.vaccine.2007.10.017","article-title":"Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge","volume":"25","author":"Frey","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.08.003_b0095","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1016\/j.vaccine.2009.06.105","article-title":"Evaluation of the efficacy of modified vaccinia Ankara (MVA)\/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model","volume":"27","author":"Garza","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.08.003_b0100","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.vaccine.2007.11.095","article-title":"Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination","volume":"26","author":"Grosenbach","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.08.003_b0105","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1073\/pnas.0912134107","article-title":"Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice","volume":"107","author":"Grosenbach","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.08.003_b0110","series-title":"Orthopoxvirus Vaccines and Vaccination","author":"Handley","year":"2007"},{"key":"10.1016\/j.antiviral.2014.08.003_b0115","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1586\/erv.09.55","article-title":"The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks","volume":"8","author":"Handley","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.antiviral.2014.08.003_b0120","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.4049\/jimmunol.177.4.2552","article-title":"Subunit recombinant vaccine protects against monkeypox","volume":"177","author":"Heraud","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2014.08.003_b0125","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/infdis\/jiq017","article-title":"Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge","volume":"203","author":"Hirao","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.08.003_b0130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/viro.1999.0096","article-title":"DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge","volume":"266","author":"Hooper","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.08.003_b0135","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1128\/JVI.78.9.4433-4443.2004","article-title":"Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox","volume":"78","author":"Hooper","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.08.003_b0140","first-page":"167","article-title":"Synthesis and antiviral evaluation of broad spectrum, orally active analogs of cidofovir and other acyclic nucleoside phosphonates","volume":"vol. 5","author":"Hostetler","year":"2007"},{"key":"10.1016\/j.antiviral.2014.08.003_b0145","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/1743-422X-9-119","article-title":"A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease","volume":"9","author":"Israely","year":"2012","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2014.08.003_b0150","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1095\/biolreprod58.1.152","article-title":"Infertility in mice induced by a recombinant ectromelia virus expressing mouse zona pellucida glycoprotein 3","volume":"58","author":"Jackson","year":"1998","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.antiviral.2014.08.003_b0155","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1128\/JVI.75.3.1205-1210.2001","article-title":"Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox","volume":"75","author":"Jackson","year":"2001","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.antiviral.2014.08.003_b0160","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1128\/AAC.01303-07","article-title":"Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor","volume":"52","author":"Jordan","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.08.003_b0165","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1016\/j.vaccine.2013.08.039","article-title":"The effects of post-exposure smallpox vaccination on clinical disease presentation: addressing the data gaps between historical epidemiology and modern surrogate model data","volume":"31","author":"Keckler","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.08.003_b0170","first-page":"84","article-title":"Expected adverse events in a mass smallpox vaccination campaign","volume":"5","author":"Kemper","year":"2002","journal-title":"Eff. Clin. Pract."},{"key":"10.1016\/j.antiviral.2014.08.003_b0175","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/infdis\/jir527","article-title":"Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults","volume":"204","author":"Kennedy","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.08.003_b0180","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.3390\/v2122740","article-title":"Development of CMX001 for the treatment of poxvirus infections","volume":"2","author":"Lanier","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2014.08.003_b0185","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.vaccine.2008.11.019","article-title":"Eczema vaccinatum resulting from the transmission of vaccinia virus from a smallpox vaccinee: an investigation of potential fomites in the home environment","volume":"27","author":"Lederman","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.08.003_b0190","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/infdis\/jis510","article-title":"Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001","volume":"206","author":"Lederman","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.08.003_b0195","series-title":"Current Protocols in Molecular Biology","first-page":"16.15.11","article-title":"Expression of proteins in mammalian cells using vaccinia cirus vectors. Overview of the vaccinia virus expression system","author":"Moss","year":"1998"},{"key":"10.1016\/j.antiviral.2014.08.003_b0200","doi-asserted-by":"crossref","first-page":"6246","DOI":"10.1128\/AAC.00977-13","article-title":"Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox)","volume":"57","author":"Mucker","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.08.003_b0205","first-page":"131","article-title":"The effectiveness of immunization with vaccinia virus type \u201cMVA\u201d against an infection with cowpox virus type \u201cOPV 85\u201d in rabbits","volume":"40","author":"Munz","year":"1993","journal-title":"Zentralbl. Veterinarmed. B"},{"key":"10.1016\/j.antiviral.2014.08.003_b0210","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/DDDT.S3687","article-title":"ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile","volume":"4","author":"Nalca","year":"2010","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.antiviral.2014.08.003_b0215","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.antiviral.2008.03.005","article-title":"Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model","volume":"79","author":"Nalca","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.08.003_b0220","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/AAC.48.6.2267-2273.2004","article-title":"Efficacy of cidofovir in a murine model of disseminated progressive vaccinia","volume":"48","author":"Neyts","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.08.003_b0225","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1086\/595565","article-title":"Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox","volume":"199","author":"Paran","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.08.003_b0230","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2217\/fvl.12.130","article-title":"A review of experimental and natural infections of animals with monkeypox virus between 1958 and 2012","volume":"8","author":"Parker","year":"2013","journal-title":"Future Virol."},{"key":"10.1016\/j.antiviral.2014.08.003_b0235","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2217\/17460913.2.1.17","article-title":"Human monkeypox: an emerging zoonotic disease","volume":"2","author":"Parker","year":"2007","journal-title":"Future Microbiol."},{"key":"10.1016\/j.antiviral.2014.08.003_b0240","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2217\/17460794.3.6.595","article-title":"Therapeutic and prophylactic drugs to treat orthopoxvirus infections","volume":"3","author":"Parker","year":"2008","journal-title":"Future Virol."},{"key":"10.1016\/j.antiviral.2014.08.003_b0245","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1177\/135965350801300703","article-title":"Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001","volume":"13","author":"Parker","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2014.08.003_b0250","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2007.08.003","article-title":"Efficacy of therapeutic intervention with an oral ether\u2013lipid analogue of cidofovir (CMX001) in a lethal mousepox model","volume":"77","author":"Parker","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.08.003_b0255","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.virol.2008.11.015","article-title":"Mousepox in the C57BL\/6 strain provides an improved model for evaluating anti-poxvirus therapies","volume":"385","author":"Parker","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.08.003_b0260","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.3390\/v2091918","article-title":"Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics","volume":"2","author":"Parker","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2014.08.003_b0265","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1016\/j.vaccine.2004.02.034","article-title":"Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB\/c mice from a lethal intranasal poxvirus challenge","volume":"22","author":"Pulford","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.08.003_b0270","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1128\/AAC.47.10.3275-3280.2003","article-title":"Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice","volume":"47","author":"Quenelle","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.08.003_b0275","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1128\/AAC.48.2.404-412.2004","article-title":"Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir","volume":"48","author":"Quenelle","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.08.003_b0280","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/AAC.00879-06","article-title":"Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice","volume":"51","author":"Quenelle","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.08.003_b0285","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1128\/AAC.00184-07","article-title":"Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice","volume":"51","author":"Quenelle","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.08.003_b0290","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1128\/AAC.00762-07","article-title":"Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses","volume":"51","author":"Quenelle","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.08.003_b0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2004.12.003","article-title":"The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4","volume":"66","author":"Robbins","year":"2005","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.08.003_b0300","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3201\/eid0706.010602","article-title":"Developing new smallpox vaccines","volume":"7","author":"Rosenthal","year":"2001","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.08.003_b0305","unstructured":"Silvera, P.M., Peter, E., Bassler, J., Gong, G., Lin, S., Hebblewaite, D., 2009. Impact of concurrent ST-246 administration on ACAM2000 vaccine efficacy in cynomolgus macaques. In: 7th ASM Biodefense Emerging Dis. Res. Meet."},{"key":"10.1016\/j.antiviral.2014.08.003_b0310","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0166-3542(01)00159-0","article-title":"Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice","volume":"52","author":"Smee","year":"2001","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.08.003_b0315","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1128\/AAC.46.5.1329-1335.2002","article-title":"Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses","volume":"46","author":"Smee","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.08.003_b0320","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1086\/422696","article-title":"Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice","volume":"190","author":"Smee","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.08.003_b0325","doi-asserted-by":"crossref","first-page":"9176","DOI":"10.1128\/JVI.02173-10","article-title":"Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus","volume":"85","author":"Smith","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.08.003_b0330","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1128\/JVI.78.13.7052-7060.2004","article-title":"Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses","volume":"78","author":"Snyder","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.08.003_b0335","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1128\/JVI.02012-09","article-title":"A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus","volume":"84","author":"Stabenow","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.08.003_b0340","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.vaccine.2005.11.022","article-title":"Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine","volume":"24","author":"Vollmar","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.08.003_b0345","first-page":"41","article-title":"Kinetics of ectromelia virus (mousepox) transmission and clinical response in C57BL\/6j, BALB\/cByj and AKR\/J inbred mice","volume":"35","author":"Wallace","year":"1985","journal-title":"Lab. Anim. Sci."},{"key":"10.1016\/j.antiviral.2014.08.003_b0350","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1128\/JVI.00984-08","article-title":"Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox","volume":"83","author":"Wei","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.08.003_b0355","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.1128\/JVI.79.20.13139-13149.2005","article-title":"An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge","volume":"79","author":"Yang","year":"2005","journal-title":"J. Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421400240X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421400240X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T18:32:04Z","timestamp":1689445924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421400240X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":71,"alternative-id":["S016635421400240X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.08.003","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}